Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation
| Autor: | Han Hsi Wong, James D. Brenton, Jonathan A. Ledermann, Christine Parkinson, Aileen Patterson, Helena M. Earl, Ashley Shaw, Mahmood I. Shafi, Michael Merger |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology endocrine system diseases Angiogenesis Nintedanib BRCA Case Report Germline chemistry.chemical_compound Ovarian cancer Ovarian carcinoma Internal medicine medicine BIBF 1120 Brca1 gene business.industry BRCA mutation Obstetrics and Gynecology medicine.disease VEGF female genital diseases and pregnancy complications Serous fluid chemistry business |
| Popis: | ► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|